Glimepiride induces proliferation and differentiation of rat osteoblasts via the PI3-kinase/Akt pathway

Metabolism: Clinical and Experimental

Volumn 59, Issue 3, 2010, Pages 359-366

  Ma, Pan ^a,b   Gu, Bin ^a   Ma, Junli ^a   E, Lingling ^a   Wu, Xia ^a   Cao, Junkai ^a   Liu, Hongchen ^a  

^a Chinese General Hospital   (China)

^b HuangShi Aesthetic Surgery Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ALKALINE PHOSPHATASE; COLLAGEN TYPE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLIMEPIRIDE; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ALKALINE PHOSPHATASE; ANIMALS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMONES; COLORING AGENTS; ENZYME INHIBITORS; HYPOGLYCEMIC AGENTS; MORPHOLINES; ONCOGENE PROTEIN V-AKT; OSTEOBLASTS; RATS; RATS, SPRAGUE-DAWLEY; SULFONYLUREA COMPOUNDS; TETRAZOLIUM SALTS; THIAZOLES;

EID: 76249088270     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2009.08.003     Document Type: Article

References (42)

1. Kemink S.A., Hermus A.R., Swinkels L.M., Lutterman J.A., and Smals A.G. Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology. J Endocrinol Invest 23 (2000) 295-303
2. Suzuki K., Sugimoto C., Takizawa M., et al. Correlations between bone mineral density and circulating bone metabolic markers in diabetic patients. Diabetes Res Clin Pract 48 (2000) 185-191
3. Vestergaard P., Rejnmark L., and Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 48 (2005) 1292-1299
4. Vestergaard P., Rejnmark L., and Mosekilde L. [Osteoporosis and fractures associated with drugs]. Ugeskr Laeger 170 (2008) 1550-1555
5. Muller G., and Geisen K. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at adipocytes. Horm Metab Res 28 (1996) 469-487
6. Kramer W., Muller G., and Geisen K. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta-cells. Horm Metab Res 28 (1996) 464-468
7. Muller G. The molecular mechanism of the insulin-mimetic/sensitizing activity of the antidiabetic sulfonylurea drug Amaryl. Mol Med 6 (2000) 907-933
8. Rodriguez E., Pulido N., Romero R., et al. Phosphatidylinositol 3-kinase activation is required for sulfonylurea stimulation of glucose transport in rat skeletal muscle. Endocrinology 145 (2004) 679-685
9. Muller G., Jung C., Wied S., Welte S., and Frick W. Insulin-mimetic signaling by the sulfonylurea glimepiride and phosphoinositolglycans involves distinct mechanisms for redistribution of lipid raft components. Biochemistry 40 (2001) 14603-14620
10. Salani B., Repetto S., Cordera R., and Maggi D. Glimepiride activates eNOS with a mechanism Akt but not caveolin-1 dependent. Biochem Biophys Res Commun 335 (2005) 832-835
11. Jojima T., Suzuki K., Hirama N., Uchida K., and Hattori Y. Glimepiride upregulates eNOS activity and inhibits cytokine-induced NF-kappaB activation through a phosphoinoside 3-kinase-Akt-dependent pathway. Diabetes Obes Metab 11 (2009) 143-149
12. Duronio V., Scheid M.P., and Ettinger S. Downstream signalling events regulated by phosphatidylinositol 3-kinase activity. Cell Signal 10 (1998) 233-239
13. Shepherd P.R., Withers D.J., and Siddle K. Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. Biochem J 333 Pt 3 (1998) 471-490
14. Martelli A.M., Borgatti P., Bortul R., et al. Phosphatidylinositol 3-kinase translocates to the nucleus of osteoblast-like MC3T3-E1 cells in response to insulin-like growth factor I and platelet-derived growth factor but not to the proapoptotic cytokine tumor necrosis factor alpha. J Bone Miner Res 15 (2000) 1716-1730
15. Carpio L., Gladu J., Goltzman D., and Rabbani S.A. Induction of osteoblast differentiation indexes by PTHrP in MG-63 cells involves multiple signaling pathways. Am J Physiol Endocrinol Metab 281 (2001) E489-499
16. Vlahos C.J., Matter W.F., Hui K.Y., and Brown R.F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269 (1994) 5241-5248
17. Abe Y., Abe T., Aida Y., Hara Y., and Maeda K. Follistatin restricts bone morphogenetic protein (BMP)-2 action on the differentiation of osteoblasts in fetal rat mandibular cells. J Bone Miner Res 19 (2004) 1302-1307
18. Abe Y., Aida Y., Abe T., et al. Development of mineralized nodules in fetal rat mandibular osteogenic precursor cells: requirement for dexamethasone but not for beta-glycerophosphate. Calcif Tissue Int 66 (2000) 66-69
19. Abe Y., Akamine A., Aida Y., and Maeda K. Differentiation and mineralization in osteogenic precursor cells derived from fetal rat mandibular bone. Calcif Tissue Int 52 (1993) 365-371
20. Brenneisen P., Wlaschek M., Schwamborn E., et al. Activation of protein kinase CK2 is an early step in the ultraviolet B-mediated increase in interstitial collagenase (matrix metalloproteinase-1; MMP-1) and stromelysin-1 (MMP-3) protein levels in human dermal fibroblasts. Biochem J 365 (2002) 31-40
21. Ulici V., Hoenselaar K.D., Gillespie J.R., and Beier F. The PI3K pathway regulates endochondral bone growth through control of hypertrophic chondrocyte differentiation. BMC Dev Biol 8 (2008) 40
22. Davies S.P., Reddy H., Caivano M., and Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351 (2000) 95-105
23. Langtry H.D., and Balfour J.A. Glimepiride. A review of its use in the management of type 2 diabetes mellitus. Drugs 55 (1998) 563-584
24. Thomas J.E., Venugopalan M., Galvin R., et al. Inhibition of MG-63 cell proliferation and PDGF-stimulated cellular processes by inhibitors of phosphatidylinositol 3-kinase. J Cell Biochem 64 (1997) 182-195
25. Osyczka A.M., and Leboy P.S. Bone morphogenetic protein regulation of early osteoblast genes in human marrow stromal cells is mediated by extracellular signal-regulated kinase and phosphatidylinositol 3-kinase signaling. Endocrinology 146 (2005) 3428-3437
26. Hou C.H., Hou S.M., and Tang C.H. Ultrasound increased BMP-2 expression via PI3K, Akt, c-Fos/c-Jun, and AP-1 pathways in cultured osteoblasts. J Cell Biochem 106 (2009) 7-15
27. Zhang Y., Zeng X., Zhang L., and Zheng X. Stimulatory effect of puerarin on bone formation through activation of PI3K/Akt pathway in rat calvaria osteoblasts. Planta Med 73 (2007) 341-347
28. Raucci A., Bellosta P., Grassi R., Basilico C., and Mansukhani A. Osteoblast proliferation or differentiation is regulated by relative strengths of opposing signaling pathways. J Cell Physiol 215 (2008) 442-451
29. Sanchez-Margalet V., Goldfine I.D., Vlahos C.J., and Sung C.K. Role of phosphatidylinositol-3-kinase in insulin receptor signaling: studies with inhibitor, LY294002. Biochem Biophys Res Commun 204 (1994) 446-452
30. Dey A., and Cederbaum A.I. Geldanamycin, an inhibitor of Hsp90 increases cytochrome P450 2E1 mediated toxicity in HepG2 cells through sustained activation of the p38MAPK pathway. Arch Biochem Biophys 461 (2007) 275-286
31. Luconi M., Torcia S., Grillo D., et al. Enhancement of mouse sperm motility by the PI3-kinase inhibitor LY294002 does not result in toxic effects on preimplantation embryo development. Hum Reprod 20 (2005) 3500-3504
32. Shingu T., Yamada K., Hara N., et al. Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells. Cancer Res 63 (2003) 4044-4047
33. Jun S.S., Chen Z., Pace M.C., and Shaul P.W. Estrogen upregulates cyclooxygenase-1 gene expression in ovine fetal pulmonary artery endothelium. J Clin Invest 102 (1998) 176-183
34. Armour K.E., and Ralston S.H. Estrogen upregulates endothelial constitutive nitric oxide synthase expression in human osteoblast-like cells. Endocrinology 139 (1998) 799-802
35. Ernst M., Heath J.K., and Rodan G.A. Estradiol effects on proliferation, messenger ribonucleic acid for collagen and insulin-like growth factor-I, and parathyroid hormone-stimulated adenylate cyclase activity in osteoblastic cells from calvariae and long bones. Endocrinology 125 (1989) 825-833
36. Oursler M.J., Cortese C., Keeting P., et al. Modulation of transforming growth factor-beta production in normal human osteoblast-like cells by 17 beta-estradiol and parathyroid hormone. Endocrinology 129 (1991) 3313-3320
37. Simoncini T., Hafezi-Moghadam A., Brazil D.P., et al. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407 (2000) 538-541
38. Kim S.J., Chun J.Y., and Kim M.S. Insulin stimulates production of nitric oxide via ERK in osteoblast cells. Biochem Biophys Res Commun 278 (2000) 712-718
39. Xie H., Tang S.Y., Luo X.H., et al. Insulin-like effects of visfatin on human osteoblasts. Calcif Tissue Int 80 (2007) 201-210
40. Zambonin G., Grano M., Greco G., Oreffo R.O., and Triffit J.T. Hydroxyapatite coated with insulin-like growth factor 1 (IGF1) stimulates human osteoblast activity in vitro. Acta Orthop Scand 70 (1999) 217-220
41. Schmid C., Steiner T., and Froesch E.R. Insulin-like growth factor I supports differentiation of cultured osteoblast-like cells. FEBS Lett 173 (1984) 48-52
42. Yamaguchi M., Ozaki K., and Hoshi T. Simulated weightlessness and bone metabolism: impairment of insulin effect on alkaline phosphatase activity in bone tissue. Res Exp Med (Berl) 191 (1991) 113-119